Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients

SCHLIEREN / ZURICH, Switzerland–(BUSINESS WIRE)–Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the closing of a CHF25 …
Read Full Story at source (may require registration)

Author
Recent Posts

Business Editor

Latest posts by Business Editor (see all)

How to Sell a Small Business: A Starter Guide for Business Owners - February 3, 2025
European Shares Drift Lower Amid France’s Debt Woes - November 27, 2024
FTSE 100 Modestly Higher In Cautious Trade - November 27, 2024

Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients

Related Posts

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZYXI

Writer/painter-turned cultural heritage preserver behind Spring Festival’s UNESCO heritage status success

Boston Hemp Launches New Line of Premium THCa Concentrates

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Bakkt Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BKKT

Kyndryl Announcement: If You Have Suffered Losses in Kyndryl Holdings, Inc. (NYSE: KD), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Australian Dollar Speculative Net Positions Improve, But Remain in the Negative

LNG Bunkering Market Poised for USD 417.8 million Valuation by 2031, to Grow at 6.5% CAGR from 2022 to 2031 | TMR Report

Latest Posts

Welcome Back!

Retrieve your password